

- Tentative Program -
JSH International Liver Conference 2019 “Liver Cirrhosis and Portal Hypertension: Modern Pathophysiology and Emerging Therapies”

Day 1: Tuesday, October 1, 2019

	[Room 1]	
08:20-08:30	Opening Remarks	
		<i>Norifumi Kawada (Osaka City University, Japan)</i>
	Session I : Epidemiology, Etiology and Basic Knowledge of Liver Cirrhosis and Portal Hypertension	
	Moderators: <i>Akio Ido, Junko Tanaka, Shuhei Nishiguchi</i>	
08:30-08:50	Stratification of Cirrhosis	
		<i>Massimo Pinzani (UCL, United Kingdom)</i>
08:50-09:10	Historical Review of Innovative Treatments for Portal Hypertension in Japan	
		<i>Naoya Murashima (Mishuku Hospital, Japan)</i>
09:10-09:30	Epidemiology, Etiology and Natural Course of Cirrhosis in Taiwan	
		<i>Jia-Horng Kao (National Taiwan University, Taiwan)</i>
09:30-09:50	Epidemiology, Etiology and Natural Course of Cirrhosis in Vietnam	
		<i>Bui Huu Hoang (University of Medicine and Pharmacy at HCMC city, Vietnam)</i>
09:50-10:00	Discussion	
10:00-10:10	Break	
	Session III : Vascular Biology of Liver Cirrhosis and Portal Hypertension	
	Moderators: <i>Jordi Gracia-Sancho, Goshi Shiota, Yutaka Sasaki,</i>	
10:10-10:30	Portal Hypertension and Vascular Biology in Liver Disease	
		<i>Don C. Rockey (Medical University of South Carolina, USA)</i>
10:30-10:50	The Pathogenesis of Liver Fibrosis and the Origin of Fibrogenic Myofibroblasts	
		<i>Tatiana Kisselva (UCSD, USA)</i>
10:50-11:10	The Regulation of Hepatic Lymphangiogenesis	
		<i>Yasuko Iwakiri (Yale University, USA)</i>
11:10-11:30	Pathology of Portal Hypertension	
		<i>Masayoshi Kage (Kurume University, Japan)</i>
11:30-11:40	Discussion	
11:40-11:50	Break	
11:50-12:45	Luncheon Seminar 1	sponsored by AbbVie GK
Moderator	<i>Tetsuo Takehara (Osaka University, Japan)</i>	
	Liver Fibrosis in the Post-HCV Era	
		<i>Massimo Pinzani (UCL, United Kingdom)</i>
12:45-14:10	Poster Session Day 1	
	Late Breaking Research I : Basic (selected oral presentations)	
	Moderators: <i>Yasuko Iwakiri, Yasunari Nakamoto, Hirohisa Yano</i>	
14:10-14:25	Selected 1	
14:25-14:40	Selected 2	
14:40-14:55	Selected 3	
14:55-15:10	Selected 4	
	Session V : Gut-Liver Axis in Cirrhosis and Portal Hypertension	
	Moderators: <i>David A Brenner, Hajime Takikawa, Masashi Yoneda</i>	
15:10-15:30	Gut-Liver Axis, Cirrhosis, and Portal Hypertension: the chicken and the egg	
		<i>Vijay H. Shah (Mayo Clinic, USA)</i>
15:30-15:50	Gut-Liver Axis in Cirrhosis and Portal Hypertension	
		<i>Ki Tae Suk (Hallym University, Republic of Korea)</i>
15:50-16:10	The Role of Gut Microbiota in Anti-tumor Immunity in Liver Tumor Microenvironment	
		<i>Naoko Ohtani (Osaka City University, Japan)</i>
16:10-16:30	Gut-Liver Axis in Chronic Liver Diseases	
		<i>Hitoshi Yoshiji (Nara Medical University, Japan)</i>
16:30-16:40	Discussion	
16:40-16:50	Break	
16:50-17:50	Evening Seminar 1	sponsored by Nihon Pharmaceutical CO., LTD
Moderator	<i>Kazuhiko Koike (University of Tokyo, Japan)</i>	
	Portal Vein Thrombosis in Patients with Liver Cirrhosis	
		<i>Hirofumi Kawanaka (National Hospital Organization Beppu Medical Center, Japan)</i>
18:30~	Social Gathering	

	[Room 2]	
	Session II : Extrahepatic Organs in Liver Cirrhosis and Portal Hypertension	
	Moderators: <i>Soon Koo Baik, Eiji Tanaka, Nobuyuki Enomoto</i>	
08:30-08:50	Diagnosis and Treatment of Hepatic Encephalopathy	
		<i>Yasuhiro Takikawa (Iwate Medical University, Japan)</i>
08:50-09:10	Diabetes in Cirrhosis and Portal Hypertension, Clinical Implication and Current Challenges	
		<i>Moon Young Kim (Yonsei University Wonju College of Medicine, Republic of Korea)</i>
09:10-09:30	Biliary Disease in Cirrhosis and Portal Hypertension	
		<i>Atsushi Tanaka (Teikyo University, Japan)</i>
09:30-09:50	The Sociology among Liver Cells, Tissues, and Organs in Alcoholic Liver Disease	
		<i>Yoshiyuki Takei (Mie University, Japan)</i>
09:50-10:00	Discussion	
10:00-10:10	Break	
	Session IV : Complications of Liver Cirrhosis and Portal Hypertension	
	Moderators: <i>Yasuhito Tanaka, Moon Young Kim, Yutaka Inagaki</i>	
10:10-10:30	3-D Imaging for Liver Cirrhosis and Portal Hypertension	
		<i>Takamichi Murakami (Kobe University, Japan)</i>
10:30-10:50	Role of Dual Red Imaging to Esophageal Varices Endoscopic Treatment	
		<i>Yoshihiro Furuichi (Tokyo Medical University, Japan)</i>
10:50-11:10	Treatment of Thrombocytopenia in Advanced Stage Liver Disease (in Europe)	
		<i>Markus Peck-Radosavljevic (Klinikum Klagenfurt, Austria)</i>
11:10-11:30	Bacterial Infection and Acute Kidney Injury in Cirrhosis	
		<i>Kuei-Chuan Lee (Taipei Veterans General Hospital, Taiwan)</i>
11:30-11:40	Discussion	
11:40-11:50	Break	
11:50-12:45	Luncheon Seminar 2	sponsored by Eisai Co., Ltd & MSD
Moderator	<i>Hitoshi Yoshiji (Nara Medical University, Japan)</i>	
	Diagnosis and surveillance for HCC: Present status and future perspective	
		<i>Ryosuke Tateishi (University of Tokyo, Japan)</i>
	Treatment strategies in advanced HCC – Focus on Lenvatinib -	
		<i>Tatsuya Yamashita (Kanazawa University, Japan)</i>
12:45-14:10	Poster Session Day 1	
	Late Breaking Research II : Translational (selected oral presentations)	
	Moderators: <i>Markus Peck-Radosavljevic, Kenichi Harada, Naoya Kato</i>	
14:10-14:25	Selected 5	
14:25-14:40	Selected 6	
14:40-14:55	Selected 7	
14:55-15:10	Selected 8	
	Session VI : IVR and Surgical Treatment for Cirrhosis and Portal Hypertension	
	Moderators: <i>Shozo Hirota, Mitsuo Shimada, Xiaolong Qi</i>	
15:10-15:30	Surgery and Basic Approach for Portal Hypertension	
		<i>Ken Shirabe (Gunma University, Japan)</i>
15:30-15:50	Surgical Treatment for Portal Hypertension	
		<i>Hiroshi Yoshida (Nippon Medical School, Japan)</i>
15:50-16:10	Portosystemic Shunt Syndrome: Pathogenesis, Hemodynamics, Diagnosis and Endovascular Management	
		<i>Wael Saad (University of Michigan, USA)</i>
16:10-16:30	BRTO in Japan	
		<i>Jun Koizumi (Tokai University, Japan)</i>
16:30-16:40	Discussion	
16:40-16:50	Break	
16:50-17:50	Evening Seminar 2	sponsored by Bayer Yakuhin, Ltd.
Moderator	<i>Hiroko Iijima (Hyogo College of Medicine, Japan)</i>	
	Therapeutic Strategy in multiple TKI era	
		<i>Atsushi Hiraoka (Ehime Prefectural Central Hospital, Japan)</i>
	Clinical impact of sequential therapy in patients with unresectable HCC~ real world data and future perspective~	
		<i>Kaoru Tsuchiya (Musashino Red Cross Hospital, Japan)</i>

08:00-08:50 **Morning Seminar 1** sponsored by MSD
 Moderator Satoshi Mochida (Saitama Medical University)
 Novel Therapeutic Strategies for Liver Fibrosis by Hepatitis C Virus
 Kiminori Kimura (Tokyo Metropolitan Komagome Hospital, Japan)
 Control and Functional Cure of HBV Infection
 Jia-Horng Kao (National Taiwan University, Taiwan)

08:50-09:00 Break

Session VII : Assessment of Liver Cirrhosis and Portal Hypertension I

Moderators: Joan Genesca, Hidetsugu Saito, Shigehiro Kokubu
 09:00-09:20 Acute Portal Hypertension Syndromes; an under recognized entity
 Shiv Kumar Sarin (Institute for Liver and Biliary Diseases Sciences, India)
 09:20-09:40 Accuracy of Viscoelasticity Measurement in Assessing Histologic Parameters in Patients with
 Nonalcoholic Fatty Liver Disease Using Shear Wave US Elastography
 Fuminori Moriyasu (Sanno Hospital, Japan)
 09:40-10:00 Non-invasive Evaluation of Liver Fibrosis
 Laurent Castera (Hôpital Beaujon, France)
 10:00-10:20 Non-Invasive Diagnosis of Liver Fibrosis by MR Elastography
 Masato Yoneda (Yokohama City University, Japan)
 10:20-10:30 Discussion
 10:30-10:40 Break

Session IX : Assessment of Liver Cirrhosis and Portal Hypertension II

Moderators: Don C. Rockey, Sumiko Nagoshi, Yoshiyuki Ueno
 10:40-11:00 Non-invasive Approaches for Diagnosis and Monitoring of Cirrhosis and Portal Hypertension: CHESS
 updates
 Xiaolong Qi (Lanzhou University, China)
 11:00-11:20 Non Invasive Assessment of Varices and CspH in Compensated Advanced Chronic Liver Disease Patients
 Joan Genesca (Universitat Autònoma de Barcelona, Spain)
 11:20-11:40 Mac-2 Binding Protein, as Glycobiomarker of Liver Fibrosis and its Biological Function
 Eiji Miyoshi (Osaka University, Japan)
 11:40-12:00 Macrophages and NK Cells as a Source of Biomarkers in Patients with NAFLD
 Tatsuya Kanto (National Center for Global Health and Medicine, Japan)
 12:00-12:10 Discussion
 12:10-12:20 Break
 12:20-13:20 **Luncheon Seminar 3** sponsored by Gilead Sciences
 Moderator Yoichi Hiasa (Ehime University, Japan)
 Update on liver fibrosis and cirrhosis
 Vincent WS Wong (The Chinese University of Hong Kong, China)

13:20-14:45 **Poster Session 2**

Late Breaking Research III: Clinical Diagnosis (selected oral presentations)

Moderators: Vijay Shah, Fumitaka Suzuki, Takuji Torimura
 14:45-15:00 Selected 9
 15:00-15:15 Selected 10
 15:15-15:30 Selected 11
 15:30-15:45 Selected 12
 15:45-16:00 Selected 13

Session XI: Emerging Therapies for Liver Cirrhosis and Portal Hypertension II

Moderators: Tatiana Kisselva, Yoshito Itoh, Laurent Castera
 16:00-16:20 Development of Anti-Fibrotic Drugs
 David A Brenner (UCSD, USA)
 16:20-16:40 Clinical Features of Sarcopenia in Patients with Chronic Liver Disease and Efficacy of Intervention with BCAA
 and Exercise
 Atsushi Hiraoka (Ehime Prefectural Central Hospital, Japan)
 16:40-17:00 Real-World Experience of Lusutrombopag for Cirrhotic Patients with Low Platelet Counts Prepared for
 Invasive Pures
 Namiki Izumi (Musashino Red Cross Hospital, Japan)
 17:00-17:20 Stem Cell Therapy For Liver Cirrhosis: Basic Study And Clinical Trial
 Shuji Terai (Niigata University, Japan)
 17:20-17:40 Transplantation of Mesenchymal Stem Cell as A New Therapeutic Option In Hepatic Fibrosis
 Soon Koo Baik (Yonsei University Wonju College of Medicine, Republic of Korea)
 17:40-17:50 Discussion
 17:50-18:00 **Closing Remarks**
 Shigehiro Kokubu (Shin Yurigaoka Hospital, Japan)

08:00-08:50 **Morning Seminar 2** sponsored by Otsuka Pharmaceutical
 Moderator Kiwamu Okita (Shunan Memorial Hospital, Japan)
 Total management of cirrhosis
 Koichi Takaguchi (Kagawa Prefectural Central Hospital, Japan)
 08:50-09:00 Break

Session VIII : Do Portal Hypertension Regress?

Moderators: Kiyoshi Hasegawa, Etsuro Hatano, Tung-Hung Su
 09:00-09:20 Regression of Portal Hypertension: Cellular and Molecular Mechanisms
 Jordi Gracia-Sancho (IDIBAPS & CIBEREHD, Spain)
 09:20-09:40 Regression of Portal Hypertension: Viral Hepatitis
 Masayuki Kurosaki (Musashino Red Cross Hospital, Japan)
 09:40-10:00 Does Portal Hypertension Regress? – Nonalcoholic Steatohepatitis
 Vincent WS Wong (The Chinese University of Hong Kong, China)
 10:00-10:20 Surgical Procedures for Portal Hypertension and NAFLD/NASH
 Masayuki Ohta (Oita University, Japan)
 10:20-10:30 Discussion
 10:30-10:40 Break

Session X: Emerging Therapies for Liver Cirrhosis and Portal Hypertension I

Moderators: Wael Saad, Naoya Sakamoto, Kenichi Ikejima
 10:40-11:00 Real World Ascites Treatment in Japan
 Masanori Atsukawa (Nippon Medical School, Japan)
 11:00-11:20 A New Era of Treatment with Antithrombin Therapy for Portal Vein Thrombosis
 Hisashi Hidaka (Kitasato University, Japan)
 11:20-11:40 Muscle Clumps and Sarcopenia
 Takumi Kawaguchi (Kurume University, Japan)
 11:40-12:00 Effects of BCAA on Prevention of Liver Failure and Carcinogenesis in Patients with Cirrhosis
 Masahito Shimizu (Gifu University, Japan)
 12:00-12:10 Discussioin
 12:10-12:20 Break
 12:20-13:20 **Luncheon Seminar 4** sponsored by Sysmex Corporation
 Moderator Masaru Harada (University of Occupational and Environmental Health, Japan)
 Remaining issues in post-virus hepatitis era-Usefulness of biomarkers in hepatic carcinogenesis and portal
 hypertension
 Hiroshi Yatsuhashi (Nagasaki Medical Center, Japan)
 Prediction of liver fibrosis progression and HCC development in NAFLD
 Keisuke Hino (Kawasaki Medical School, Japan)

13:20-14:45 **Poster Session 2**

Late Breaking Research IV: Clinical Therapy (selected oral presentations)

Moderators: Kazuhiko Nakao, Mitsuhiro Moriyama Hiroshi Yotsuyanagi
 14:45-15:00 Selected 14
 15:00-15:15 Selected 15
 15:15-15:30 Selected 16
 15:30-15:45 Selected 17
 15:45-16:00 Selected 18

Session XII: Emerging Therapies for Liver Cancer from Cirrhosis

Moderators: Shiv Kumar Sarin, Norihiro Kokudo, Hiroaki Nagano
 16:00-16:20 Occurrence of Hepatocellular Carcinoma from Cirrhosis
 Tung-Hung Su (National Taiwan University Hospital, Taiwan)
 16:20-16:40 Pathology Diagnosis of Tumor Microenvironment of HCC
 Michiie Sakamoto (Keio University, Japan)
 16:40-17:00 Prevention and Risk for Liver Cancer after Anti-Viral Therapy in Patients with HBV/HCV
 Yasuhiro Asahina (Tokyo Medical and Dental University, Japan)
 17:00-17:20 Development of Immunotherapy for Hepatocellular Carcinoma
 Eishiro Mizukoshi (Kanazawa University, Japan)
 17:20-17:40 Molecular Targeted Therapy for Liver Cancer
 Masatoshi Kudo (Kindai University, Japan)
 17:40-17:50 Discussion